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Objective. Squamous cell carcinoma of the oral tongue (SCCOT) is one of the most common malignant carcinomas in the
head and neck. Recurrence and/or metastasis often results in failure of treatment and decreases the survival of the patients. The
purpose of this study is to investigate the effect of gene-silence of Kif2a on SCCOT in viro and in vivo.
Study design. Plasmid-mediated expression of Kif2a-siRNA (pGPU6/GFP/Kif2a) was employed to silence the expression of
Kif2a in Tca8113 cells at both mRNA and protein levels. Tca8113 cell proliferation was measured by 3-(4,5-dimethylthiazol-
2-yl)-2, 5-diphenyltetrazolium bromide (MTT) assay and growth of Tca8113 tumors was determined by intra-tumor injection of
pGPU6/GFP/Kif2a in nude mice.
Results. Gene-silence of Kif2a suppressed Tca8113 cell proliferation. pGPU6/GFP/Kif2a synergized the tumor suppression
effect of 5-Fluorouracil (5-Fu) on Tca8113 cells.
Conclusions. Our data support that Kif2a is a potential molecular target for the therapeutics of recurrent and metastatic
SCCOT. (Oral Surg Oral Med Oral Pathol Oral Radiol 2013;116:49-54)Squamous cell carcinoma of the oral tongue (SCCOT) is
one of the most common cancers in the oral cavity that
belongs to squamous cell carcinomas of the head and neck
(SCCHN). Although early diagnosis and local manage-
ment have improvedpatients’ chances of survival and their
quality of life,1 the treatment of SCCOT has remained
technically and physically difﬁcult, especially those with
local and regional recurrences. In recent years, a multidis-
ciplinary approach to SCCOT has begun to offer many
clinical beneﬁts mainly due to the addition of chemo-
therapy to radiotherapy.2,3 Nevertheless, the severity of
toxicity and the side-effects of radiochemotherapy remain
major obstacles during treatment of SCCOT.2
Currently, molecular targeted interventions in pre-
clinical and clinical settings have become important for
the treatment of SCCOT. For instance, the use of
inhibitors of epidermal growth factor receptor (EGFR)
or its monoclonal antibodies (cetuximab) has been
demonstrated to signiﬁcantly prolong patients’ survival.This work was supported by Grants from National Natural Science
Foundation of China (Nos. 81202142, 81201947 and 81201654).
aLecturer, Department of Pathology, Medical College of Qingdao
University.
bProfessor/Attending Physician, Department of Pathology, The
Afﬁliated Hospital of Medical College, Qingdao University.
cProfessor, College of Life Science/Tianjin Key Laboratory of Cyto-
Genetical and Molecular Regulation, Tianjin Normal University.
dProfessor, Institute of Basic Medical Sciences, Qilu Hospital,
Shandong University.
eProfessor, Department of Stomatology, Qilu Hospital, Shandong
University.
Received for publication Nov 4, 2012; returned for revision Jan 4,
2013; accepted for publication Jan 26, 2013.
 2013 Elsevier Inc.
2212-4403
http://dx.doi.org/10.1016/j.oooo.2013.01.028
Open access under CC BY-NC-ND license.These two novel methods have been proven to be the
most effective treatment for recurrent and/or metastatic
SCCHN.4 However, other promising biological targets
more speciﬁc for SCCOT still needs to be explored.
Generally, tumor metastasis is known as cancer cells
leaving the original tumor site and migrating to neigh-
boringordistant tissues. InSCCOT, tumormetastasis often
results in the occurrence of more aggressive and malignant
carcinomas, which subsequently leads to the failure of the
treatment of SCCOT.5 In our previous study, 44 cases of
primary tumors and their corresponding adjacent tissues
were analyzed.6 These results, together with the in vitro
studies on SCCOT-derived Tca8113 cells, indicated that
Kif2a, a microtubule based motor protein, is involved in
the progression, invasion, and metastasis of SCCOT.
In the current study, using 3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide (MTT) assay, we
further examined the inhibitory effect of gene silence of
Kif2a on Tca8113 cells via siRNA expression vector of
pGPU6/GFP/Kif2a. In addition, we investigated the
therapeutic effect of pGPU6/GFP/Kif2a on Tca8113
cells alone or in combination with 5-ﬂuorouracil (5-Fu),
one of the most widely used chemotherapeutic drugs for
SCCHN, in vitro and in vivo.Statement of Clinical Relevance
We investigated synergistic effects of Kif2a gene-
silence and 5-ﬂuorouracil treatment on SCCOT cells
in vitro and in vivo. Our studies suggest Kif2a as
a potent biological molecule used in target thera-
peutics for recurrent and/or metastatic SCCOT.
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Fig. 1. Effects of pGPU6/GFP/Kif2a treatment on Tca8113 cells. Tca8113 cells were transfected with the pGPU6/GFP only,
pGPU6/GFP/NC or pGPU6/GFP/Kif2a. After 48 h, the expression of Kif2a mRNA in the group transfected with pGPU6/GFP/
Kif2a was decreased signiﬁcantly than other two groups (A). After 72 h, the expression of Kif2a protein in group transfected with
pGPU6/GFP/Kif2a was decreased apparently than other two groups (C). b-actin was used as a control. pGPU6/GFP/NC was used
as a negative control. Data were expressed as the gray-scale ratio of Kif2a mRMA or protein relative to that of b-actin (B,D). All
data were presented as mean standard deviation (SD). All the experiments were repeated at least 3 times. *P< .01 as compared
with injection of pGPU6/GFP/NC.
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Plasmids
The sequence of Kif2a-siRNA (Ambion, USA) is: 50-
GGCAAAGAGAUUGACCUGG-30, which was reported
in previous study.7 siRNA expression vectors were con-
structed by introducing synthetic double-stranded oligo-
nucleotides (Kif2a: 50-CACCGGCAAAGAGATTGACC
TGGTTCAAGAGACCAGGTCAATCTCTTTGCCTT
TTTTG-30; Negative control: 50-CACCGTTCTCC
GAACGTGTCACGTCAAGAGATTACGTGACACG
TTCGGAGAATTTTTTG-30) into the pGPU/GFP/Neo
vector (GenePharma Inc., Shanghai, China), and de-
scribed as pGPU6/GFP/Kif2a, pGPU6/GFP/NC, res-
pectively. All constructs were fully sequenced. An
unengineered plasmid, pGPU6/GFP, was used as a blank
control.
Cell lines and transfection
Human tongue squamous cell carcinoma cell lines
(Tca8113 cells) were purchased from Culture Collection
of Chinese Academy of Science (Shanghai, China). The
culture medium is Dulbecco’s modiﬁed Eagle’s medium
(DMEM; Gibco) containing 10% fetal bovine serum
(Gibco, New York, NY, USA), penicillin (100 units/mL),
and streptomycin (100 mg/mL). The cells are cultured at
37 C in a humidiﬁed air atmosphere containing 5%CO2.
For transfection, the cells were seeded at 70%-80%
conﬂuence in 6-well plates, and were transfected with
pGPU6, pGPU6/GFP/NC and pGPU6/GFP/Kif2a withLipofectmine 2000 (Invitrogen Corporation, Carlsbad,
CA, USA) in serum-free Opti-MEM (Invitrogen, Carls-
bad, CA, USA) according to the instructions. The
concentration of DNA vectors for transfection was 4 mg/
mL in a ﬁnal volume of 500 mL. The cells were washed
after 4 h incubation and resuspended in complete growth
medium with serum for further experiments.Semi-quantitative reverse transcription polymerse
chain reaction analysis
Forty-eight hours after transfection, total RNA was
prepared using TRIZOL reagent (Invitrogen, USA)
according to the manufacturer’s protocol, and cDNA was
synthesized by the First Strand cDNA Synthesis kit (Fer-
mentas, Vilnius, Lithuania). The thermocycler conditions
used for ampliﬁcation were cycles of 94C for 4 min,
94C for 30 s, 55C for 30 s, and 72C for 45 s. The
primers were commercially prepared (Shanghai Sangon,
China) and the sequences were as follows: Kif2a: forward
50-GCCTTTGATGACTCAGCTCC-30, reverse 50-TT
CCTGAAAAGTCACCACCC-30. b-actin: forward 50-
AGCGAGCATCCCCCAAAGTT-30, reverse 50-GGGC
ACGAAGGCTCATCATT-30.Western blot analysis
Immunoblotting assay was performed as previously
described.8 In brief, 72 h after transfection, cells were
collected and lysed in 1% NP-40 lysis buffer. The cell
Fig. 2. Gene-silence of Kif2a in Tca8113 cells suppresses cell growth in vitro. pGPU6/GFP, pGPU6/GFP/NC or pGPU6/GFP/
Kif2a transfected Tca8113 cells were cultured for 24, 48, or 72 h. The cell proliferation was analyzed by MTT assay. Absorbance
was measured at 570 nm. The data were presented as the means of six separated experiments, each performed in triplicate. Cell
numbers were counted on 24, 48, or 72 h. The absorbance of MTT (A) and cell growth curves (B) were shown. *P< .05 as
compared with injection of pGPU6/GFP/NC.
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a minigel apparatus and transferred to polyvinylidene
ﬂuoride (PVDF) membrane. The membrane was blotted
with rabbit anti-Kif2a polyclonal antibodies at 1:10,000
dilutions (Abcam Inc., Cambridge, MA, USA) for 2 h
at room temperature. Blots were exposed to horseradish
peroxidase (HRP)-conjugated goat anti-rabbit IgG
(1:10,000 dilution) followed by development using
enhanced chemiluminescence (ECL) reagent. Band
density was measured by photoimage analysis using the
Quantity one software (Bio-Rad, Hercules, CA, USA),
and expressed as the percentage of density of the
respective house-keeping b-actin.MTT assay
Tca8113 cells were plated in 96-well plates (6000/well)
and transfected as mentioned above. In the following
24, 48 and 72 h, cells were assayed using MTT method.
In brief, 20 mL of 5 mg/mL MTT was added into each
well and the cells were incubated for 4 h. Then the cell
culture medium was removed followed by adding
another 200 mL of dimethyl sulfoxide (DMSO). Thirty
minutes later, the plates were placed on a micro-plate
auto-reader (Bio-Rad). Optical density (OD) was read
at 570 nm wavelength and the values were analyzed by
Microsoft Excel software.Animal model and delivery of plasmid-mediated
RNA interference
Six-week-old male BALB/c nude mice with average
body weights of 20-25 g (Slac, Shanghai, China) were
prepared for tumor implantation. The present study was
performed in accordance with the guidelines of the
National Institutes of Health Guide for the Care and Use
of Laboratory Animals (NIH Pub. No. 85-23, revised,
1996) and was approved by Animal Care and Use
Committee of the Medical college of Shandong
University. All animals were maintained in a sterileenvironment. Cages, bedding, food, and water were all
autoclaved. All animals were maintained on a daily 12-h
light and 12-h dark cycle. Tca8113 cells were collected,
washed twice, and resuspended in phosphate buffered
saline (PBS). Cell number and viability were determined
by staining a small volume of cell suspension with
a 0.2% trypan blue saline solution and examining the
cells in a hemocytometer (Countstar, Shanghai, China).
Tca8113 cells (5 106/mouse) were injected subcuta-
neously (SC) into the ﬂanks of nude mice.
After four weeks, SC tumors reached 1.5 cm in
diameter and were harvested. The periphery of the
tumors was trimmed off and used for surgical ortho-
topic implantation. The tissues were cut into small
pieces of 1 mm3 in size. To ensure that all the mice
were implanted with equally viable tissue, the tissue
fragments were mixed thoroughly before implanta-
tion. Sixty mice were anesthetized with ethylether
inhalation and the back was chosen for orthotopic
implantation. Then the tumor pieces were put into
a sterilized core needle and delivered into the back
SC, and a core of the needle push the tumor pieces
into the right place.
Intra-tumor injection was used as a strategy to deliver
siRNA expressing plasmids. One week after implanta-
tion, when the tumor’s size reached about 2 mm in
diameter, the tumor-bearing animals were randomly
divided into 3 groups for intra-tumor injection: (1)
pGPU6/GFP/Kif2a; (2) pGPU6/GFP/NC; and (3) equal
volume of normal saline as blank control. To facilitate
delivery of the vectors in vivo, Lipofectmine 2000
(Invitrogen Corporation) was applied in the fol-
lowing ratio:vector (mg):Lipo (vol):OPTI (vol)¼
1 mg:3 mL:100 mL. Intra-tumor injection was performed
every three days, and tumor growth was evaluated by
tumor volume weekly for eight consecutive weeks,
during which 16 intra-tumor injection were made.
Tumor volume (V) was calculated according to the
fomula V (mm3)¼ lengthwidth2 0.5.
Fig. 3. Intra-tumor injection of pGPU6/GFP/Kif2a reduces the size of Tca8113 tumors. Intra-tumor injection of pGPU6/GFP/Kif2awith
Lipofectamine 2000 signiﬁcantly reduces the size of Tca8113 tumors implanted subcutaneously in nudemice during the 8-week follow-
up period as compared with pGPU6/GFP and pGPU6/GFP/NC controls. Tumor volume was calculated according to the formula:
volume¼width2 length/2 as shown in (B), and theﬁnal tumor sampleswere photographed (A). *P< .01 as comparedwith injection of
pGPU6/GFP/NC.
Table I. IC50 of 5-Fu (mean standard deviation) in
different cells
IC50 (mM)
pGPU6/GFP 35.089  1.9510*,y
pGPU6/GFP/NC 32.550  2.5430*,z
pGPU6/GFP/Kif2a 14.745  2.3600y,z
*pGPU6/GFP vs. pGPU6/GFP/NC, P¼ .321.
ypGPU6/GFP vs. pGPU6/GFP/Kif2a, P¼ .009.
zpGPU6/GFP/NC vs. pGPU6/GFP/Kif2a, P¼ .024.
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In vitro, cell chemosensitivity to 5-Fu was evaluated by
MTT analysis. Seventy-two hours after transfection, the
cells in the96-wellswere treatedwith serial concentrations
of 5-Fu at 0, 2.5, 5, 10, 20, 40, 80, and 160 mM. The cell
viability was detected as described above 48 h later. The
inhibitory ratio was calculated by the following formula:
Inhibitory ratio ð%Þ ¼
1 average absorbance of treated group
average absorbance of control group

 100%
The 50% concentration of inhibition (IC50) were
calculated by the Calcusyn software package (Biosoft,
Cambridge, UK).
The tumor sensitivity to 5-Fu was evaluated in the
mouse model when subcutaneous tumors reached the
size of about 1 cm in diameter. The tumor-bearing
animals were randomly divided into 4 groups for intra-
tumor injection: (1) pGPU6/GFP/Kif2a; (2) pGPU6/
GFP/NC; (3) pGPU6/GFP; and (4) nothing as blank
control. At the same time, 5-Fu was intravenously (IV)
injected via the tail veins at a dosage of 8 mg/kg, and
the tumor sizes were measured weekly up to 8 weeks.RESULTS
Vector-mediated RNAi inhibits Kif2a expression
Vector-mediated RNA interference targeting Kif2a was
performed by reverse transcription polymerse chainreaction (RT-PCR) andWestern blot analyses. TheKif2a
mRNAexpressionwas reduced by approximately 80% in
pGPU6/GFP/Kif2a-transfected cells compared to
pGPU6/GFP/NCor PGPU6/GFP treated cells (Figure 1A
and B, P< .01). Meanwhile, Western blot showed that
the expression of Kif2a protein was signiﬁcantly sup-
pressed in pGPU6/GFP/Kif2a-treated Tca8113 cells
compared to pGPU6/GFP/NC or pGPU6/GFP trans-
fection controls (Figure 1C andD,P< .01). These results
indicated that pGPU6/GFP/Kif2a had a gene-silencing
effect on Kif2a at both mRNA and protein levels.
Gene-silence of Kif2a inhibits proliferation of
Tca8113 cells
In order to examine the effects of Kif2a gene silence on
Tca8113 cells, we transfected Tca8113 cells with pGPU6/
GFP/Kif2a, pGPU6/GFP/NC and pGPU6/GFP, respec-
tively. After each cell lines were cultured in 96-well plates
for 24, 48, or 72 h, MTT assays were performed and
growth curves of cells were illustrated according to OD
values (Figure 2A, P< .05). Here pGPU6/GFP/Kif2a
transfected cells grew more slowly than either pGPU6/
GFP/NC or pGPU6/GFP tranfected Tca8113 cells while
there was no signiﬁcant difference between the latter two
types of cells. On cell images that were photographed on
an invert microscope, there appeared a much less number
of pGPU6/GFP/Kif2a transfected cells compared with the
numbers of pGPU6/GFP/NC and pGPU6/GFP tranfected
cells by the 48th hour (Figure 2B, P< .05).
Gene-silence of Kif2a inhibits tumor growth in vivo
In order to investigate whether Kif2a RNAi was capable
of inhibiting tumor growth in vivo, intra-tumor injection
with siRNA-expressing plasmids was performed. During
the 8 consecutive weeks of tumor growth in vivo, there was
no animal death or other complications, such as skin ne-
crosis, resulting from transfection. As shown in Figure 3,
the tumor size was smaller in pGPU6/GFP/Kif2a treated
animals compared with the pGPU6/GFP/NC and saline
Fig. 4. Kif2a RNAi synergizes with 5-Fu suppressing the growth of Tca8113 tumors. Tca8113 cells were transfected with pGPU6/
GFP, pGPU6/GFP/NC or pGPU6/GFP/Kif2a and treated with indicated concentration of 5-Fu 72 h later. The cell proliferation was
detected by MTT assay 48 h after 5-Fu treatment. *P< .01 as compared with pGPU6/GFP/NC transfected cells (A). Tca8113 cells
were implanted subcutaneously into nude mice. When tumor size reaches 1 cm in diameter, the mice received intra-tumor injection
of pGPU6/GFP, pGPU6/GFP/NC or pGPU6/GFP/Kif2a, followed by intravenous injection of 5-Fu via tail vein at a dosage of
8 mg/kg. Tumor size was measured weekly up to 8 weeks. *P< .01 as compared with pGPU6/GFP/NC injected mice (B).
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differences became more signiﬁcant at the end of the
observation. The tumor sizes of pGPU6/GFP/Kif2a injec-
ted mice were 2652.46 203.93 mm3 after 8 weeks,
whereas those of the pGPU6/GFP/NC and saline tre-
ated animals were 4847.3 329.67 and 4679.30
378.11 mm3, respectively (P< .01). During the 2-8 weeks
of observation, growth inhibition was also observed in the
pGPU6/GFP/NC treated tumors compared with the saline
treated group, whichmay have resulted from the toxicity of
the liposome transfection reagent. However, at the end
point of the experiment, no difference in tumor sizes was
observed between these two groups (P> .05). The entire
duration of the experiment was 12 weeks.Gene-silence of Kif2a synergizes chemotherapeutic
inhibition of tumor growth
Since gene-silence of Kif2a has been shown to suppress
the growth of Tca8113 cells, we proposed that it could be
used to enhance chemotherapeutic inhibition of tumor
cells. Since 5-Fu is one of the most common drugs for
chemotherapy of SCCOT,9 we next investigated the
effect of Kif2a gene-silence on 5-Fu-mediated Tca8113
cells growth inhibition. In MTT assays, the IC50 of 5-Fu
in the pGPU6/GFP/Kif2a transfected cells was
14.745 2.3600 mM, which was signiﬁcantly lower
than that of the pGPU6/GFP/NC (32.550 2.5430 mM,
P< .05) or pGPU6/GFP transfected cells
(35.089 1.9510 mM, P< .01) (Table I and Figure 4A).
Consistent with the in vitro chemosensitivity result,
tumor inhibition of 5-Fu in vivo was also signiﬁcantly
improved by Kif2a RNAi. As shown in Figure 4B, the
tumor growth in the pGPU6/GFP/Kif2aþ 5-Fu treated
animals was inhibited to a greater extent compared with
the pGPU6/GFP/NCþ 5-Fu, pGPU6/GFPþ 5-Fu or
5-Fu only treated groups. At the end point of the
chemosensitivity study, the average tumor size was873.4 106.54 mm3 in pGPU6/GFP/Kif2aþ 5-Fu
treated animals, signiﬁcantly smaller than the control
groups (1545.60 54.74 mm3 in pGPU6/GFP/NCþ 5-
Fu,1483.7 108.56 mm3 in pGPU6/GFPþ 5-Fu or
1583.30 91.63 mm3 in 5-Fu only treated ones)
(P< .01). Collectively, these results showed that Kif2a
RNAi had a synergistic effect on chemotherapeutic 5-Fu.DISCUSSION
SCCOT is one of the most common malignant carci-
nomas in the head and neck. Local advanced resectable
tumors treated by surgery and radiotherapy have been
reported to show better prognosis.10 However, recur-
rence and/or metastasis of local or regional tumors
remains the largest obstacle in the treatment of SCCOT.5
A multidisciplinary approach, including induction
chemotherapy, concurrent chemotherapy and radio-
therapy, is currently widely used for the treatment of
advanced and/or metastatic forms of SCCOT.2,3,11
Recently, a targeted molecular therapy has been reported
to greatly improve prognoses of this malignant disease,
e.g., Cetuximab, a monoclonal antibody of EGFR.12,13
However, more potential biological targets for the treat-
ment and therapy of SCCOT need to be explored.
Previously, we identiﬁed that Kif2a, a microtubule
motor protein in the Kinesin-13 family, is involved in the
progression, invasion and metastasis of SCCOT.6 In this
study, we further investigated the effects of gene silence
ofKif2a onTca8113 cells.We demonstrated that plasmid
vector-mediated expression of Kif2a-siRNA can efﬁ-
ciently knock down the expression of Kif2a gene at both
mRNA and protein levels in Tca8113 cells, and results in
inhibition of tumor cell growth in vitro and in vivo. Our
results provide solid evidence that depletion of Kif2a can
suppress the growth of Tca8113 cells. We can draw
a conclusion that Kif2a can be used as a potential target
for the treatment of SCCOT.
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and Kif2a gene-silence on Tca8113 cells. We observed
a potent synergistic anti-cancer effect ofKif2aRNAi and5-
Fu. Tumor growth was signiﬁcantly suppressed both
in vitro and in vivo when Kif2a gene silence was used in
combination with 5-Fu IV. The mechanism of such
synergism is not yet clear. 5-Fu has beenwidely used in the
treatment of head and neck squamous cell carcinoma
(HNSCC), especially in recurrent and/or metastatic
HNSCC.14,15 It has been reported that 5-Fu shows greater
inhibition rates than other commonly used anti-cancer
drugs, such as CDDP, BLM, TXT, etc.9 5-Fu is known to
arrest cells into the G1 phase of the cell cycle and then
induce cells to undergo apoptosis.16,17 Kif2a has been
demonstrated as a crucialmotorprotein required for normal
accomplishment of cell division.8,18 The synergism of
Kif2a gene silence with 5-Fu appears to provide a novel
anti-cancer strategywith improved therapeutic efﬁcacyand
reduced dosage and toxicity of 5-Fu. As shown in the
present study, combination of 5-Fu and Kif2a RNAi
demonstrated remarkable inhibitory effect on Tca8113
cells which further prove the signiﬁcance of Kif2a in the
treatment of SCCOT as a novel biological target.
In conclusion, this study has shown that gene silence
of Kif2a in Tca8113 cells not only signiﬁcantly inhibit
proliferation of the cells, but also enhances tumor-
inhibitory effect of 5-Fu both in vitro and in vivo. These
data provide substantial evidence that Kif2a is prom-
ising to be employed as a molecular target in the
treatment of recurrent and/or metastatic SCCOT, espe-
cially in combination with 5-Fu. We look forward to the
development of strategies that deliver Kif2a RNAi
vectors into cancer cells with low toxicity and high
efﬁciency in the near future.
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